List view / Grid view
Scientists at the University of Sydney have discovered a malfunctioning brain protein linked to Parkinson’s - which could lead to new therapies for the debilitating condition in the future.
Scientists have developed a new AI-guided tool that predicts how bowel cancer becomes resistant to treatment – which could lead to development of new personalised therapies.
Kipu Quantum and IonQ have set a new benchmark in quantum computing by solving the most complex protein folding problem ever tackled on quantum hardware – creating potential for real-world applications in drug discovery.
Think drug discovery is slow? This biotech is moving faster, smarter and deeper – by asking the question that no one else has.
Researchers from UT Health San Antonio have identified the CST protein complex as a key driver of resistance to PARP inhibitors in BRCA1-deficient cancers – which could lead to more personalised treatments for breast, ovarian and prostate cancer patients.
Researchers have developed a novel gene therapy approach that reactivates dormant genes by repositioning them closer to genetic switches called enhancers - showing promise for treating blood disorders like sickle cell disease.
Researchers at the Fralin Biomedical Research Institute are developing a targeted KCNT1 inhibitor that has shown early promise in reducing seizures in preclinical models.
Chiesi Group and Key2Brain have signed a global license agreement to develop two blood-brain barrier-crossing enzyme replacement therapies for alpha-mannosidosis and Krabbe disease – with the aim to help patients with limited treatment options.
Fauna Bio has launched Fauna Brain™, a powerful new AI platform that leverages the company’s expertise in comparative genomics to accelerate drug target discovery.
Researchers at Southern Medical University have developed a self-propelled ferroptosis nanoinducer that penetrates deeper into tumour tissues - offering a new strategy for safer and more effective cancer treatment.
A new material developed at Cornell University offers a more effective way to deliver mRNA vaccines by replacing polyethylene glycol (PEG) with a water-loving polymer poly(carboxybetaine) (PCB).
A practicing surgeon turned biotech CEO is developing a novel pain medicine that could sidestep the failures of both opioids and paracetamol.
Centauri Therapeutics has published data showing that CTX-09’s ability effectively clears drug-resistant Gram-negative bacteria through a novel dual mechanism, marking a promising development for new infection therapies.
President Trump’s proposed drug pricing reforms are putting pressure on early-stage discovery. To keep pace, teams must rethink how they manage risk, resources and collaboration.
A new study at Science Tokyo has developed patient-derived organoids to better understand and combat resistance in oesophageal squamous cell carcinoma (ESCC).
